- Ticlopidine hydrochloride
- Clopidogrel bisulfate
- Duloxetine hydrochloride
- Duloxetine intermediate
- Clopidogrel intermediate
- Mirtazapine intermediates
- Dabigatran etexilate intermediates
- Febuxostat intermediates
- Vildagliptin intermediates
- Solifenacin Intermediates
- Drotaverine intermediates
- Prasugrel Intermediates
- Thiophene class
- Verapamil, Denopamine intermediates
- Denopamine, Zatebradine intermediates
- Oxolinic acid, Cinoxacin, Miloxacin intermediate
- Ticagrelor intermediate <Under Development>
- Saxagliptin intermediate <Under Development>
Tel / Fax: +86-576-85300870
Zhejiang Liaoyuan Pharmaceutical Co., Ltd. is located in Zhejiang Provincial Chemical and Medical Raw Materials Base- Linhai Industrial Zone, covering an area of 136,000 square meters with a total investment of RMB 200 million. Liaoyuan is a cGMP certified enterprise, Zhejiang New high-tech enterprise, ISO9001 and ISO14001 certified enterprise, and Zhejiang AAA credit enterprise. As a joint stock company, Liaoyuan is entering a phase of preparation for listing.
Liaoyuan focuses on manufacturing APIs and intermediates for anticoagulants, antidepressants and cardiovascular drugs. The leading products include Clopidogrel, Ticlopidine Hydrochloride, Mirtazapine, and ect. Liaoyuan enjoys a good reputation as a manufacturer of thiophene derivatives; especially it is the largest supplier of 2-thiophene ethanol and 2-thiophene ethylamine in the global market.
Liaoyuan has a provincial high-tech R&D center, combined with high investment in R&D, which can ensure the advanced technology among the same industry all over the world.” Viewing quality of product as the life of an enterprise, the internal controls of Liaoyuan are strictly in accordance with cGMP standard. Based on the spirit “people oriented” and “science and technology invigorating an enterprise”, senior managerial staff and technicians who have good ability to develop and research new high-tech productions account for 35% of the company.
The prospect goal of Liaoyuan is to build a medium sized enterprise with advanced technology and an annual turnover of RMB 1000 million in the coming 3-5 years by means of strengthening modern enterprise management and ensuring constantly technical innovation.